[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613338":3},{"organization":4,"outcomesModule":7,"designInfo":43,"detailedDescription":42,"studyPopulation":42,"armGroups":54,"interventions":67,"overallOfficials":42,"centralContacts":75,"locations":81,"responsibleParty":101,"collaborators":42,"id":103,"slug":42,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":42,"eligibilityCriteria":108,"healthyVolunteers":104,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":42,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":42,"overallStatus":84,"whyStopped":42,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":42},[9,13],{"measure":10,"description":11,"timeFrame":12},"Percentage of patients achieving Psoriasis Area and severity index(PASI) 75 at week 16","PASI 75 is defined as at least a 75% reduction in PASI relative to baseline","week 16",{"measure":14,"description":15,"timeFrame":12},"Percentage of patients achieving an static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) at Week 16","sPGA of psoriasis is used to determine the participant's psoriasis lesions overall.",[17,20,23,26,28,31,34,36,38,40],{"measure":18,"description":19,"timeFrame":12},"Percentage of patients achieving PASI 50 at week 16","PASI 50 is defined as at least a 50% reduction in PASI relative to baseline",{"measure":21,"description":22,"timeFrame":12},"Percentage of patients achieving PASI 90 at week 16","PASI 90 is defined as at least a 90% reduction in PASI relative to baseline",{"measure":24,"description":25,"timeFrame":12},"Percentage of patients achieving PASI 100 at week 16","PASI 100 is defined as at least a 100% reduction in PASI relative to baseline",{"measure":27,"description":15,"timeFrame":12},"Percentage of patients achieving an sPGA 0 at week 16",{"measure":29,"description":30,"timeFrame":12},"Percentage of patients achieving an Children Dermatology life quality index (CDLQI) Score of 0 \u002F1at week 16","The CDLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life",{"measure":32,"description":11,"timeFrame":33},"Percentage of patients achieving PASI 75 at week 56","week 56",{"measure":35,"description":22,"timeFrame":33},"Percentage of patients achieving PASI 90 at week 56",{"measure":37,"description":25,"timeFrame":33},"Percentage of patients achieving PASI 100 at week 56",{"measure":39,"description":15,"timeFrame":33},"Percentage of patients achieving an sPGA 0\u002F1 at Week 56",{"measure":41,"description":15,"timeFrame":33},"Percentage of patients achieving an sPGA 0 at Week 56",null,{"allocation":44,"interventionModel":45,"interventionModelDescription":42,"primaryPurpose":46,"observationalModel":42,"timePerspective":42,"maskingInfo":47},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":48,"maskingDescription":42,"whoMasked":49},"QUADRUPLE",[50,51,52,53],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[55,61],{"label":56,"type":57,"description":58,"interventionNames":59},"placebo","PLACEBO_COMPARATOR","Participants receive placebo through week 16,placebo participants will cross over to receive IBI112 through week 44",[60],"Drug: placebo",{"label":62,"type":63,"description":64,"interventionNames":65},"IBI112","EXPERIMENTAL","Participants receive IBI112 through week 44",[66],"Drug: IBI112",[68,72],{"type":69,"name":62,"description":70,"armGroupLabels":71,"otherNames":42},"DRUG","IBI112 by subcutaneous injection",[62],{"type":69,"name":56,"description":73,"armGroupLabels":74,"otherNames":42},"placebo by subcutaneous injection",[56],[76],{"name":77,"role":78,"phone":79,"phoneExt":42,"email":80},"Bingjing Feng","CONTACT","+86 18361923769","bingjing.feng@innoventbio.com",[82],{"facility":83,"status":84,"city":85,"state":86,"zip":87,"country":88,"countryCode":89,"cosmosGeoPoint":90,"geoPoint":95,"contacts":96},"Beijing Children's Hospital Affiliated to Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100000","China","CN",{"type":91,"coordinates":92},"Point",[93,94],116.39723,39.9075,{"lat":94,"lon":93},[97],{"name":98,"role":78,"phone":99,"phoneExt":42,"email":100},"Zigang Xu","+86 1337011021","zigangxupek@163.com",{"type":102,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100613338",false,"NCT07265284","A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis","A Phase Ⅰ\u002FⅢ Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Picankibart in Adolescent Patients With Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\nMales or females aged 12 to 18 years; Diagnosed with plaque psoriasis and a history of psoriasis ≥6 months; suitable for phototherapy and\u002For systemic treatment for psoriasis.\n\nExclusion Criteria:\n\nHistory of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis Has received any therapeutic agent directly targeted to IL-17within 6 months of the first administration of study agent Has received any therapeutic agent directly targeted toTNF-a within 3 months of the first administration of study agent Has received any conventional therapeutic agent within 1 months of the first administration of study agent Has received any topic therapeutic agent within 2 weeks of the first administration of study agent Hsa received IBI112","ALL","12 Years","18 Years",{"count":113,"type":114},104,"ESTIMATED","INTERVENTIONAL",[117],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.",[120],"Psoriasis","2025-12-19",{"date":123,"type":124},"2025-12-22","ACTUAL",{"date":126,"type":124},"2025-12-03",{"date":128,"type":114},"2029-01-31",{"name":5,"class":6},1]